Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 55

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 55
---
 of the Summary Compensation Table. (2) Amounts represent the RSUs granted to our NEOs in January 2024, July 2024 and September 2024 pursuant to our long-term equity incentive program and in August 2024 to promote stability in our leadership team during a period of CEO transition. Other than the one-time RSU awards granted on August 1, 2024 to certain NEOs, the RSUs vest over a four-year period, with 25% of the shares vesting on each of the first, second, third and fourth anniversaries of the first day of the month in which the RSU was granted, provided that the recipient provides continuous service to the Company. The one-time RSUs granted on August 1, 2024 to Messrs. Pakola, Danos and Christmas vest over a two-year period, with 25% of the RSUs vesting every six months from the grant date, provided that the recipient provides continuous service to the Company. (3) Amounts represent the options granted to our NEOs in January 2024, July 2024 and September 2024 pursuant to our long-term equity incentive program. These options vest over a four-year period, with 25% of the shares vesting after 12 months from the date of grant and the balance vesting in equal monthly installments over the 36 months thereafter, provided that the optionee provides continuous service to the Company. (4) Amounts represent the aggregate grant date fair value of RSUs and options granted during 2024 calculated in accordance with FASB ASC Topic 718. See Note 11, “Stock-based Compensation,” to the financial statements included in our Annual Report for a discussion of the assumptions we made in determining the grant date fair value of our equity awards.

<div align='center'>39</div>

Outstanding Equity Awards at 2024 Fiscal Year-End The following table sets forth information regarding outstanding and unexercised options and unvested RSUs held by each of our NEOs as of December 31, 2024. The number of shares subject to each award and, where applicable, the exercise price per share, reflects all changes as a result of our capitalization adjustments. The vesting schedule applicable to each outstanding award is described in the footnotes to the table below.

|                      |     |              |     | Option Awards(1) |     |               |     |                 |     |                   |     |                               Stock Awards